162 related articles for article (PubMed ID: 21517810)
21. Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Aguiar Bujanda D; Cabrera Suárez MA; Bohn Sarmiento U; Quintero Pérez S; Aguiar Morales J
Clin Transl Oncol; 2006 Dec; 8(12):919-21. PubMed ID: 17169767
[TBL] [Abstract][Full Text] [Related]
22. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
Mozzati M; Martinasso G; Maggiora M; Scoletta M; Zambelli M; Carossa S; Oraldi M; Muzio G; Canuto RA
Clin Oral Investig; 2013 May; 17(4):1259-66. PubMed ID: 22864527
[TBL] [Abstract][Full Text] [Related]
23. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
24. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
Sarasquete ME; González M; San Miguel JF; García-Sanz R
Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Wong YK; Cheng JC
Quintessence Int; 2008 Mar; 39(3):195-201. PubMed ID: 18618033
[TBL] [Abstract][Full Text] [Related]
26. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
27. [Bisphosphonates-related jaw osteonecrosis].
Abi Najm S; Lysitsa S; Carrel JP; Lesclous P; Lombardi T; Samson J
Presse Med; 2005 Sep; 34(15):1073-7. PubMed ID: 16334883
[TBL] [Abstract][Full Text] [Related]
28. [Zoledronate-related maxillary osteonecrosis].
Borrás Blasco J; Rosique Robles D; Giner Marco V; Galán Brotons A
Farm Hosp; 2006; 30(3):197-9. PubMed ID: 16999570
[No Abstract] [Full Text] [Related]
29. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
30. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Aguiar Morales J
Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Infante Cossío P; Cabezas Macián A; Pérez Ceballos JL; Palomino Nicas J; Gutiérrez Pérez JL
Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E52-7. PubMed ID: 18167482
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.
Suleman YF; Meer S; Lurie R
Head Neck Pathol; 2007 Dec; 1(2):156-64. PubMed ID: 20614268
[TBL] [Abstract][Full Text] [Related]
33. Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
Fusco V; Loidoris A; Colella G; Vescovi P; Campisi G
Breast; 2010 Oct; 19(5):432-3; author reply 433-4. PubMed ID: 20363135
[No Abstract] [Full Text] [Related]
34. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
Bagan JV; Jimenez Y; Murillo J; Hernandez S; Poveda R; Sanchis JM; Diaz JM; Scully C
Oral Oncol; 2006 Mar; 42(3):327-9. PubMed ID: 16275156
[No Abstract] [Full Text] [Related]
35. [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
Lund T; Gregersen H; Vangsted A; Marker P; Abildgaard N
Ugeskr Laeger; 2009 Jan; 171(1-2):50-2. PubMed ID: 19128568
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonate-related osteonecrosis of the jaws--a case report.
Kamoh AK; Ogle O
Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
[TBL] [Abstract][Full Text] [Related]
37. [Maxillary osteonecrosis associated with the use of zoledronate: Presentation of three cases].
Puigoriol EB; Tuneu NC; Danés CF; Domingo JP
Aten Primaria; 2010 Oct; 42(10):534-5. PubMed ID: 20129709
[No Abstract] [Full Text] [Related]
38. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
Diego R; D'Orto O; Pagani D; Agazzi A; Marzano U; Derada Troletti G; Fontanella W; Pignataro L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):e1-5. PubMed ID: 17197204
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
Del Conte A; Bernardeschi P; La Ferla F; Turrisi G; D'Alessandro M; Montagnani F; Fiorentini G
J Oral Maxillofac Surg; 2010 May; 68(5):1179-82. PubMed ID: 20185222
[No Abstract] [Full Text] [Related]
40. Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.
Junquera L; Gallego L; Villarreal P
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1229-31. PubMed ID: 19015457
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
